Innovent Biologics, Inc. and GenFleet Therapeutics on 21 August scored China’s first approval for a KRAS G12C inhibitor, the co-developed Dupert (fulzerasib), winning a head start over foreign and domestic rivals to unlock a national market where roughly 50,000 patients are expected to be diagnosed with lung cancer harboring the drug's targeted mutation in 2025.
Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
Homegrown Competition Looming
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
